Evidence map›Paper›PMID 23526959›Full record

Trial reportPloS one2013

The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial.

Aprilianto E Wiria, Firdaus Hamid, Linda J Wammes, Maria M M Kaisar, Linda May, Margaretta A Prasetyani, Sitti Wahyuni, Yenny Djuardi, Iwan Ariawan, Heri Wibowo and 14 more

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 4 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

24 authors at 6 institutions in 4 countries.

Aprilianto E WiriaDepartment of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Firdaus Hamid
Linda J Wammes
Maria M M Kaisar
Linda May
Margaretta A Prasetyani
Sitti Wahyuni
Yenny Djuardi
Iwan Ariawan
Heri Wibowo
Bertrand Lell
Robert Sauerwein
Gary T Brice
Inge Sutanto
Lisette van Lieshout
Anton J M de Craen
Ronald van Ree
Jaco J Verweij
Roula Tsonaka
Jeanine J Houwing-Duistermaat
Adrian J F Luty
Erliyani Sartono
Taniawati Supali
Maria Yazdanbakhsh
Leiden University Medical Center · NLUniversity of Indonesia · IDRadboud University Nijmegen · NLAcademic Medical Center · NLAlbert Schweitzer Hospital · GAHasanuddin University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelminth infections are proposed to have immunomodulatory activities affecting health outcomes either detrimentally or beneficially. We evaluated the effects of albendazole treatment, every three months for 21 months, on STH, malarial parasitemia and allergy. METHODS AND

findingsA household-based cluster-randomized, double-blind, placebo-controlled trial was conducted in an area in Indonesia endemic for STH. Using computer-aided block randomization, 481 households (2022 subjects) and 473 households (1982 subjects) were assigned to receive placebo and albendazole, respectively, every three months. The treatment code was concealed from trial investigators and participants. Malarial parasitemia and malaria-like symptoms were assessed in participants older than four years of age while skin prick test (SPT) to allergens as well as reported symptoms of allergy in children aged 5-15 years. The general impact of treatment on STH prevalence and body mass index (BMI) was evaluated. Primary outcomes were prevalence of malarial parasitemia and SPT to any allergen. Analysis was by intention to treat. At 9 and 21 months post-treatment 80.8% and 80.1% of the study subjects were retained, respectively. The intensive treatment regiment resulted in a reduction in the prevalence of STH by 48% in albendazole and 9% in placebo group. Albendazole treatment led to a transient increase in malarial parasitemia at 6 months post treatment (OR 4.16(1.35-12.80)) and no statistically significant increase in SPT reactivity (OR 1.18(0.74-1.86) at 9 months or 1.37 (0.93-2.01) 21 months). No effect of anthelminthic treatment was found on BMI, reported malaria-like- and allergy symptoms. No adverse effects were reported.

conclusionsThe study indicates that intensive community treatment of 3 monthly albendazole administration for 21 months over two years leads to a reduction in STH. This degree of reduction appears safe without any increased risk of malaria or allergies.

trial registrationControlled-Trials.com ISRCTN83830814.

Indexed as

AdolescentAdultAlbendazoleAnthelminticsChildChild, PreschoolDouble-Blind MethodDrug Administration ScheduleFemaleHelminthiasisHumansHypersensitivityIndonesiaMalariaMaleMiddle AgedAlbendazoleAnthelminticsSoil

Identifiers

PMID23526959
PMCPMC3602425
OpenAlexW2028368894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.